Kat60 lacking the MIT domain or the MIT domain and linker region is not detectably degraded in cells. by Kyle D. Grode (725568)

Decreased Risk of Ventilator-Associated Pneumonia in Sepsis Due to Intra-Abdominal Infection by François Philippart (319324)

“…The IAI group had fewer patients with VAP (56 [19.3%] <i>vs</i>. 806 [34.5%], <i>P</i><0.01) and longer time to VAP (5.0 <i>vs</i>.10.5 days; <i>P</i><0.01). After adjustment on independent risk factors for VAP and previous antimicrobial use, IAI was associated with a decreased risk of VAP (hazard ratio, 0.62; 95% confidence interval, 0.46–0.83; <i>P</i><0.0017). …”

Crosslinking decreases the alignment of fibers associated with individual cells migrating out of spheroids. by Michael Pamonag (12295175)

Depletion of Kat80 reduces steady-state Kat60 levels in cells. by Kyle D. Grode (725568)

Kat60 lacking the MIT domain disassembles microtubules at high levels of accumulation in cells. by Kyle D. Grode (725568)

Intracellular Ca²⁺ signaling and IP3R2 expression are decreased in <i>Tcirg1</i>-knockdown osteoclasts. by Dongyan Zhang (640677)

Kat60 lacking the MIT domain does not disassemble microtubules at low levels of accumulation in cells. by Kyle D. Grode (725568)

Inducible expression of Kat60 results in measurable microtubule disassembly in our single-cell assay. by Kyle D. Grode (725568)

Simulation results predict the role of AC in driving the in-phase behavior and decreasing time delay for inversely out-of-phase behavior. by Lingxia Qiao (19996756)

A functional PSA mimetic peptide (fPSA) prevents glutamate-induced MAP-2 decrease and concomitant changes in SYN and NCAM synaptic patterns and levels. by María Fernanda Podestá (639243)

“…^#P<0.05; ^## P<0.01; ^### P<0.001 between bars, two-way ANOVA followed by Bonferroni test. Scale bars: 50 µm. fPSA: functional PSA mimetic peptide; MAP-2: microtubule-associated protein 2; NCAM: neural cell adhesion molecule; SYN: synaptophysin.…”

MeCP2 expression in glutamatergic dLGN neurons decreases upon dark-rearing. by Yuki Yagasaki (402238)

In-phase (A) and opposed phase (B) chemical shift MR images of a 51-year-old male demonstrate hepatic steatosis, consistent with areas of decreased signal intensity on an opposed-p... by Andrzej Cieszanowski (635105)

histomorphometric results obtained on 2D histological sections or on 3D models prepared by microCT. by Eric Aguado (687890)

Genes showing decreased expression in D381 following 2h exposure to Doxycycline. by Wanjun Qi (5571359)

Ki67 and cyclin D2 mRNA is significantly decreased relative to age. by Yanhui Huang (656379)

“…<p>qRT-PCR was used to analyze Ki67 and cyclin D2 mRNA levels. Both Ki67 (A) and cyclin D2 (B) were decreased with age. …”

CHIKV-infected primary joint tissue fibroblasts display decreased MHC-I cell surface expression. by Brian C. Ware (8544672)

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Both with somatic and with dendritic stimulation, pyramidal cell burst firing decreases as the apical dendrite becomes shorter. by Ronald A. J. van Elburg (80591)